---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-005477"
form_type: "8-K"
ticker: "PBYI"
cik: "0001401667"
company_name: "PUMA BIOTECHNOLOGY, INC."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:28:10.315861+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Puma Biotechnology reports Q4 GAAP net income $19.3M ($0.39 EPS); guides FY2025 net income $23-28M

## Summary
- Q4 product revenue net $54.4M (up from $53.2M YoY); full year $195.2M (down from $203.1M).
- GAAP net income $30.3M ($0.62/share) for FY2024 vs. $21.6M ($0.46) in FY2023.
- Non-GAAP adjusted net income $38.5M ($0.79/share) for FY2024 vs. $31.8M ($0.68) in FY2023.
- Cash and securities $101M at Dec 31, 2024; operating cash flow $38.9M for FY2024.
- FY2025 guidance: net product revenue $192-198M; net income $23-28M (excludes valuation allowance).

## SEC filing metadata
- accession: 0001437749-25-005477
- form_type: 8-K
- ticker: PBYI
- cik: 0001401667
- company_name: PUMA BIOTECHNOLOGY, INC.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/0001437749-25-005477-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/pbyi20250224_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-005477
- JSON: https://secwatch.observer/filing/0001437749-25-005477.json
- Plain text: https://secwatch.observer/filing/0001437749-25-005477.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.